TrialSignal
Clinical trial intelligence report
An Open-label, Multi-Center, Phase IIIb Study to Assess the Safety and Efficacy of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia Who Are Eligible for "7+3" or "5+2" Chemotherapy
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03379727-Jul 28, 2026
NCT ID
NCT03379727
Status
COMPLETED
Phase
Phase 3b
Sponsor
Novartis Pharmaceuticals
Executive brief
Investment-Ready Snapshot
Midostaurin (PKC412), developed by Novartis Pharmaceuticals, targets FLT3 mutations in AML, a significant market segment with unmet needs. The combination of midostaurin with standard chemotherapy regimens (7+3 or 5+2) aims to improve patient outcomes in newly diagnosed FLT3-mutated AML. The study's completion and the anticipated results could strengthen Novartis's position in the oncology market, particularly against competitors like Astellas and Daiichi Sankyo, which also target FLT3 mutations. Successful outcomes may enhance market access and reimbursement opportunities, while potential adverse events could impact market perception and adoption.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03379727
Indication
Acute Myeloid Leukemia
Modality
small molecule
Target
Fms-like tyrosine kinase receptor (FLT3) mutations (ITD or TKD) in Acute Myeloid Leukemia (AML)
Intervention
Midostaurin, Cytarabine, anthracycline ((daunorubicin or idarubicin): Induction Phase only
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.